Emyria (ASX:EMD) entered a multi-year agreement with Medibank (ASX: MPL) to fund treatment for screened and eligible customers admitted into the firm's treatment-resistant depression program at Perth Clinic, according to a Monday Australian bourse filing.
The firm said that this was the first time a major private health insurer was funding a psychotherapy-led treatment-resistant depression program in Australia.
The firm's shares jumped 6% in recent trading on Monday and earlier reached their highest point in over a year.